Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer

Published:2004-07-28 Issue:4 Volume:292 Page:470
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Delbaldo Catherine,Michiels Stefan,Syz Nathalie,Soria Jean-Charles,Le Chevalier Thierry,Pignon Jean-Pierre

Publisher

American Medical Association (AMA)

Subject

General Medicine

Cited by 301 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of an m6A Natural Inhibitor, Lobeline, That Reverses Lenvatinib Resistance in Hepatocellular Tumors;Journal of Natural Products;2024-08-13

2. Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy;Frontiers in Cell and Developmental Biology;2024-05-15

3. Overcoming drug resistance with specific nano scales to targeted therapy: Focused on metastatic cancers;Pathology - Research and Practice;2024-03

4. Non-Small Cell Lung Cancer;Tata Memorial Centre Textbook of Oncology;2024

5. Continuation of immunotherapy beyond progression is beneficial to the survival of advanced non-small-cell lung cancer;Clinical and Translational Oncology;2023-12-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP